Human Immunology News

Human Immunology News is an online publication and email newsletter for researchers studying the human immune system.

Enhancement Of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma

January 21, 2025

[Clinical Cancer Research] In this first trial combining a poly(ADP-ribose) polymerase inhibitor with high-dose chemotherapy, olaparib/vorinostat/GemBuMel was safe and showed promising activity in refractory lymphomas, including post-CAR-T relapses.

Clonal Analysis of SepSecS-Specific B and T Cells in Autoimmune Hepatitis

January 21, 2025

[Journal of Clinical Investigation] To analyze the immune response to O-phosphoseryl-tRNA:selenocysteine-tRNA synthase (SepSecS) in patients with autoimmune hepatitis at the clonal level, scientists combined sensitive high-throughput screening assays with the isolation of monoclonal antibodies and T cell clones.

The CD4/CD8 Ratio Is Associated with T Lymphocyte Functions in Long-Term Virally Suppressed Patients with HIV

January 21, 2025

[BMC Infectious Diseases] Researchers explored the association between the CD4/CD8 ratio and T lymphocyte activities in people living with HIV.

Intercellular TIMP-1-CD63 Signaling Directs the Evolution of Immune Escape and Metastasis in KRAS-Mutated Pancreatic Cancer Cells

January 21, 2025

[Molecular Cancer] Scientists investigated how KRAS-mutated epithelial cells acquired the capacity to escape senescence or even immune clearance, thereby progressing to advanced pancreatic ductal adenocarcinoma.

mtSTAT3 Suppresses Rheumatoid Arthritis by Regulating Th17 and Synovial Fibroblast Inflammatory Cell Death with IL-17-Mediated Autophagy Dysfunction

January 21, 2025

[Experimental & Molecular Medicine] The authors investigated the novel role of mitochondrial STAT3 (mitoSTAT3) in Th17 cells and fibroblast-like synoviocytes (FLSs) and analyzed the correlation of mitoSTAT3 with rheumatoid arthritis.

EXamining the Feasibility of exerCisE to Manage Symptoms of Lupus (EXCEL): A Protocol for a Randomized Controlled Pilot Study

January 21, 2025

[Lupus Science & Medicine] EXCEL examined the feasibility of conducting a large-scale randomized controlled trial comparing the effects of a remotely monitored, home-based, exercise program with standard of care for individuals with systemic lupus erythematosus.

Linifanib Alone and in Combination with Metronomic Chemotherapy Is Active on Cutaneous T Cell Lymphoma Cells by Targeting the AKT/mTOR Signaling Pathway

January 21, 2025

[Investigational New Drugs] Investigators evaluated the in vitro antitumor activity of the multi-kinase inhibitor linifanib, either alone or in combination with metronomic vinorelbine or etoposide, on cutaneous T cell lymphomas cells.

Recent Clinical and Mechanistic Insights into Vitiligo Offer New Treatment Options for Cell-Specific Autoimmunity

January 21, 2025

[Journal of Clinical Investigation] Recent translational research has revealed key mechanisms of vitiligo, including cellular stress, innate immune activation, T cell-mediated elimination of melanocytes from the skin resulting in clinically apparent white spots, and stem cell regeneration that reverses established lesions.

Hinge Bio Raises $30 Million Series A’ Financing to Develop Next-Generation Therapies via its Proprietary GEM-DIMER Platform

January 21, 2025

[Hinge Bio, Inc.] Hinge Bio, Inc. announced the close of a Series A’ financing led by Point72 where proceeds will support the entry of the company’s lead product candidate, HB2198, into a Phase I clinical trial in patients living with systemic lupus erythematosus.

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

January 21, 2025

[Vera Therapeutics, Inc.] Vera Therapeutics, Inc. announced an exclusive license agreement with Stanford University for a novel, next-generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell-mediated diseases.

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—The Phase III...

January 7, 2025

[Journal of Clinical Oncology] The MECCA trial demonstrated a significant improvement in progression-free survival and overall survival with first-line metronomic capecitabine plus aromatase inhibitor (AI) compared with AI alone in patients with hormone receptor-positive+/HER2-negative metastatic breast cancer.

Intratumoural CD8+ CXCR5+ Follicular Cytotoxic T Cells Have Prognostic Value and Are Associated with CD19+ CD38+ B Cells and Tertiary Lymphoid Structures in Colorectal...

January 7, 2025

[Cancer Immunology Immunotherapy] Researchers explored the characteristics of follicular cytotoxic T cells in colorectal cancer (CRC) and compared their biological functions between microsatellite instability-high and microsatellite stability CRC.

Each issue of Human Immunology News provides up-to-date coverage of the latest news in immunology research performed using human cells or subjects. Our expert editors hand-pick recent research papers and review articles from relevant high-impact peer-reviewed journals on topics including immunotherapy, autoimmunity, adaptive, and innate immunity in humans. We also feature news on clinical trials, award announcements, and funding opportunities.